美托洛尔联合厄贝沙坦治疗高血压性心脏病的疗效观察  

Therapeutic effects of metoprolol combined with irbesartan on hypertensive heart disease

作　　者：蒋宏亮[1] 

机构地区：[1]海南省海口市人民医院,570208

出　　处：《河北医药》2017年第17期2597-2599,共3页Hebei Medical Journal

摘　　要：目的探讨联合使用美托洛尔与厄贝沙坦在治疗高血压性心脏病中的疗效。方法选取2015年10月至2016年5月就诊的高血压性心脏病患者132例,根据随机数字原则,患者分为试验组(n=67)和对照组(n=65),对照组患者服用厄贝沙坦,试验组患者服用美托洛尔及厄贝沙坦。比较2组患者治疗3个月后的血压情况、心功能分级情况、相关血液指标(包括血糖、三酰甘油、肌酐、胆固醇、丙氨酸氨基转移酶等)。根据疗效评定标准,对2组患者的治疗效果做出评定和比较。结果 2组患者治疗前收缩压和舒张压差异无统计学意义(P>0.05)。治疗3个月后,2组患者的血压均有明显下降(P<0.05),试验组患者的舒张压和收缩压下降的幅度都明显大于对照组(P<0.05)。2组患者治疗前纽约心脏协会(new york heart association,NYHA)心功能分级差异无统计学意义(P>0.05),但治疗后2组间差异有统计学意义(P<0.05)。2组患者的相关血液检测指标,包括血糖、三酰甘油、肌酐、胆固醇及丙氨酸氨基转移酶升高差异无统计学意义(P>0.05)。试验组治疗总有效率显著高于试验组(P<0.05)。结论联合使用美托洛尔和厄贝沙坦治疗高血压性心脏病,能够有效降低患者血压,改善心功能,同时安全性较高,值得在临床上推广。Objective To investigate the therapeutic effects of metoprolol combined with irbesartan on hypertensive heart disease.Methods A total of 132 patients with hypertensive heart disease who were treated in our hospital from October 2015 to May 2016 were randomly divided into two groups,trial group （n=67） and control group （n=65）.The patients in control group were treated by oral irbesartan ,however,the patients in trial group,on the basis of control group were treated by metoprolol.After 3-month treatment, the blood pressure,heart function classification,related blood indexes including blood glucose, triglyceride,creatinine,cholesterol and alanine aminotransferase were observed and compared between two groups.Besides,the therapeutic effects were evaluated and compared between two groups.Results Before treatment,there were no significant differences in systolic pressure and diastolic pressure between two groups （P〉0.05）.However after 3-month treatment,the levels of blood pressure were obviously decresased in both groups （P〈0.05）, moreover the decrease degree of systolic pressure and diastolic pressure in trial group was more obvious than that in control group （P〈0.05）.According to the heart function classification criteria （NYHA）,there was no significant difference in heart function classification between two groups before treatment （P〉0.05）,however,after treatment, there was a significant difference in heart function classification between two groups （P〉0.05）.There were no significant differences in blood glucose, triglyceride, creatinine, cholesterol and alanine aminotransferase between two groups （P〉0.05）.Furthermore the total effective rate in trial group was significantly higher than that in control group （P〈0.05）.Conclusion The combination application of metoprolol with irbesartan in treatment of hypertensive heart disease can effectively reduce blood pressure,improve heart function,with good safety, thus,which is worth using widely in clinical practice.

关 键 词：高血压性心脏病 美托洛尔 厄贝沙坦 治疗结果 

分 类 号：R541.3[医药卫生—心血管疾病]